secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001701541-23-000045
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics Q3 net loss $23.0M; cash $144.3M; advances BDTX-1535 and BDTX-4933 trials
--------------------------------------------------------------------------------

- Net loss $23.0M vs $21.7M in Q3 2022; R&D $16.2M, G&A $7.9M (includes CEO transition costs).
- Cash, cash equivalents, and investments $144.3M at Sep 30, 2023; expected to fund operations into H1 2025.
- BDTX-1535 Phase 1 expansion cohorts enrolling; initial NSCLC expansion data expected 2024; GBM dose escalation data later 2023.
- BDTX-4933 Phase 1 trial dosed first patient; targeting KRAS, NRAS, BRAF mutations; dose escalation ongoing.
- Mark Velleca appointed President and CEO in September 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154123000045/0001701541-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154123000045/bdtx-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001701541-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer